nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

15.04.2021 | case report

Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review

verfasst von: Anis Chaari, MD, Esraa Turak, Mark Nashaat, Islam Aboayana, Vipin Kauts

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Summary

Mucormycosis is a rare but potentially life-threatening disease. Common risk factors include diabetic ketoacidosis, malignancies and bone marrow transplant. In patients with hematological malignancies mucormycosis often occurs in a context of neutropenia and/or following chemotherapy. We report a case of sphenoidal mucormycosis in a patient with large B‑cell lymphoma. This complication happened before any chemotherapy. The patient had normal neutrophils count and his diabetes was well controlled. Clinical course and management are discussed along with a review of the literature.

Vorheriger Artikel Cryptococcus neoformans meningitis in a patient with diffuse large B-cell lymphoma—a case report

Nächster Artikel Novel agents in a young patient with osteosarcoma: A short review

Itoh M, et al. Disseminated mucormycosis infection after the first course of dose-modified R‑EPOCH for advanced-stage lymphoma. Kansenshogaku Zasshi. 2014;88(6 Suppl 11):7–10.PubMed

Roden MM, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.CrossRef

Tryfon S, et al. Rhinocerebral mucormycosis in a patient with latent diabetes mellitus: a case report. J Oral Maxillofac Surg. 2002;60(3):328–30.CrossRef

Alacacioglu I, et al. Fatal disseminated mucormycosis in a patient with mantle cell non-Hodgkin’s lymphoma: an autopsy case. Braz J Infect Dis. 2009;13(3):238–41.CrossRef

Cornely OA, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.CrossRef

Bahloul M, et al. Rhinocerebral mucormycosis complicated by hemophagocytic lymphohistiocytosis: case report from Tunisia. Med Sante Trop. 2012;22(2):210–2.PubMed

Chaari A, et al. Mucormycosis: an unusual cause of unilateral exophthalmia. J Mycol Med. 2013;23(2):140–3.CrossRef

Hilal AA, Taj-Aldeen SJ, Mirghani AH. Rhinoorbital mucormycosis secondary to Rhizopus oryzae: a case report and literature review. Ear Nose Throat J. 2004;83(8):556–558–60, 562.CrossRef

Valentine JC, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005–2016. BMC Infect Dis. 2019;19(1):274.CrossRef

10.

Chamilos G, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91(7):986–9.PubMed

11.

Nosari A, et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica. 2000;85(10):1068–71.PubMed

12.

Pagano L, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell’Adulto). Br J Haematol. 1995;89(3):500–5.CrossRef

13.

Spellberg B, Edwards J Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.CrossRef

14.

Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74(1):150–60.CrossRef

15.

Lewis RE, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638–45.CrossRef

16.

Pagano L, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto). Br J Haematol. 1997;99(2):331–6.CrossRef

17.

Lerchenmüller C, et al. Rhinocerebral zygomycosis in a patient with acute lymphoblastic leukemia. Ann Oncol. 2001;12(3):415–9.CrossRef

18.

Nithyanandam S, et al. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003;51(3):231–6.PubMed

19.

Mistro S, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54(12):1774–7.CrossRef

20.

Rodríguez MM, et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother. 2009;53(12):5022–5.CrossRef

21.

Rodríguez MM, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54(5):1665–9.CrossRef

Titel: Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review
verfasst von: Anis Chaari, MD
Esraa Turak
Mark Nashaat
Islam Aboayana
Vipin Kauts
Publikationsdatum: 15.04.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00705-5

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Lethal human metavirus pneumonia in a patient with chronic lymphocytic leukemia

Multiple myeloma: my highlights at ASH 2020

Therapy concepts in the context of precision medicine for pediatric malignancies—children are not adults

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis

Clinically relevant infections in hematatology and oncology

Decision making in hematology—chronic myeloid leukemia